These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31251112)

  • 41. A robust Bayesian dose-finding design for phase I/II clinical trials.
    Liu S; Johnson VE
    Biostatistics; 2016 Apr; 17(2):249-63. PubMed ID: 26486139
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials.
    Zhang L; Yuan Y
    Stat Med; 2016 Nov; 35(27):4924-4936. PubMed ID: 27580928
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bayesian Design for Identifying Cohort-Specific Optimal Dose Combinations Based on Multiple Endpoints: Application to a Phase I Trial in Non-Small Cell Lung Cancer.
    Horton BJ; Wages NA; Gentzler RD
    Int J Environ Res Public Health; 2021 Oct; 18(21):. PubMed ID: 34769970
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The quasi-CRM shift method for partially ordered groups.
    Celum C; Horton BJ; Conaway M
    Contemp Clin Trials; 2024 Jan; 136():107400. PubMed ID: 38000453
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles.
    Yin J; Qin R; Ezzalfani M; Sargent DJ; Mandrekar SJ
    Stat Med; 2017 Jan; 36(1):67-80. PubMed ID: 27633877
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Toxicity and Efficacy Probability Interval Design for Phase I Adoptive Cell Therapy Dose-Finding Clinical Trials.
    Li DH; Whitmore JB; Guo W; Ji Y
    Clin Cancer Res; 2017 Jan; 23(1):13-20. PubMed ID: 27742793
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Introduction of Oncology Dose-Finding Trial Designs].
    Takeda K
    Gan To Kagaku Ryoho; 2022 Apr; 49(4):365-370. PubMed ID: 35444116
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Uniformly most powerful Bayesian interval design for phase I dose-finding trials.
    Lin R; Yin G
    Pharm Stat; 2018 Nov; 17(6):710-724. PubMed ID: 30066466
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Competing designs for drug combination in phase I dose-finding clinical trials.
    Riviere MK; Dubois F; Zohar S
    Stat Med; 2015 Jan; 34(1):1-12. PubMed ID: 24464821
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Bayesian phase I/II design to determine subgroup-specific optimal dose for immunotherapy sequentially combined with radiotherapy.
    Guo B; Zang Y; Lin LH; Zhang R
    Pharm Stat; 2023 Jan; 22(1):143-161. PubMed ID: 36161762
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Probability-of-decision interval 3+3 (POD-i3+3) design for phase I dose finding trials with late-onset toxicity.
    Xu Z; Lin X
    Stat Methods Med Res; 2022 Mar; 31(3):534-548. PubMed ID: 34806915
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bayesian dose-finding phase I trial design incorporating pharmacokinetic assessment in the field of oncology.
    Takeda K; Komatsu K; Morita S
    Pharm Stat; 2018 Nov; 17(6):725-733. PubMed ID: 30066356
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adaptive Phase I clinical trial design using Markov models for conditional probability of toxicity.
    Fernandes LL; Taylor JM; Murray S
    J Biopharm Stat; 2016; 26(3):475-98. PubMed ID: 26098782
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials.
    Yuan Y; Lin R; Li D; Nie L; Warren KE
    Clin Cancer Res; 2018 Oct; 24(20):4921-4930. PubMed ID: 29769209
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Small-sample behavior of novel phase I cancer trial designs.
    Oron AP; Hoff PD
    Clin Trials; 2013 Feb; 10(1):63-80. PubMed ID: 23345304
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Application of Bayesian hierarchical models for phase I/II clinical trials in oncology.
    Yada S; Hamada C
    Pharm Stat; 2017 Mar; 16(2):114-121. PubMed ID: 27892650
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Shift models for dose-finding in partially ordered groups.
    Horton BJ; Wages NA; Conaway MR
    Clin Trials; 2019 Feb; 16(1):32-40. PubMed ID: 30309262
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A benchmark for dose-finding studies with unknown ordering.
    Mozgunov P; Paoletti X; Jaki T
    Biostatistics; 2022 Jul; 23(3):721-737. PubMed ID: 33409536
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials.
    Chen Z; Yuan Y; Li Z; Kutner M; Owonikoko T; Curran WJ; Khuri F; Kowalski J
    Contemp Clin Trials; 2015 Jul; 43():133-41. PubMed ID: 26012358
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dose finding with continuous outcome in phase I oncology trials.
    Wang Y; Ivanova A
    Pharm Stat; 2015; 14(2):102-7. PubMed ID: 25408518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.